Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

INTRODUCTION: Daratumumab is a CD38-targeting monoclonal antibody that has demonstrated clinical benefit for multiple myeloma. Daratumumab inhibition of CD38, which is expressed on immune cell populations and cardiomyocytes, could potentially affect cardiac function. This QTc substudy of the phase 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Chari, Ajai, Munder, Markus, Weisel, Katja, Jenner, Matthew, Bygrave, Ceri, Petrucci, Maria Teresa, Boccadoro, Mario, Cavo, Michele, van de Donk, Niels W. C. J., Turgut, Mehmet, Demirkan, Fatih, Karadogan, Ihsan, Libby, Edward, Kleiman, Robert, Kuppens, Steven, Bandekar, Rajesh, Neff, Tobias, Heuck, Christoph, Qi, Ming, Clemens, Pamela L., Goldschmidt, Hartmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889563/
https://www.ncbi.nlm.nih.gov/pubmed/33474705
http://dx.doi.org/10.1007/s12325-020-01601-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889563/
https://www.ncbi.nlm.nih.gov/pubmed/33474705
http://dx.doi.org/10.1007/s12325-020-01601-w

Ejemplares similares